Member Info for Mozax

Just on their Website and reading the presentation of the 21st October 2024.

Indeed, somehow they own 52.5% of the Giant Block 2A (Kertang).

Farm out Underway - intense industry interest.

• TargetEquity(postfarm-down):15.75%

• NetMeanProspectiveResources3:

1.4 TCF + 23 mmbbl (261 mmboe)

• ChanceofSuccess3:~22%

• Potentialunriskedvalue(£/share). : £14.65

Interesting.

Have a peek at Orcadian, ORCA, MCap now sub £4M and check out their assets.

I say again, the x 2 500K trades yesterday around 0.65p were buys, I know this as they were mine.

I’ll confirm later the exact price I paid when I’m back at my desk & can look in my account.

No ramping required, PYC is at an all time low but with potentially significant news around the corner.

I note VAL had a minor retrace this morning, to be expected after an 80% rise but it’s about to go blue again, suggesting there is some confidence in the news from the presentation.

It seems Bly follows that if the News for VAL does land, there will be a significant re-rate here.

£6M and 6% of royalties , risk reward etc.

I confirm buys we’re printed red at 0.65p

Low freefloat here so the SP moves quickly in either direction, depending on sentiment.

Clearly, investors are worried about what Labour will announce on the 30th, and the SP has declined rather unpleasantly.

However, 79M shares x 5p gives an MCap of £3.95M, which is very low given what Orcadian Hold.

Let’s see where we stand in November, could be very significant upside here.

LSE fault here as ALGW closed up 5.68% and MM’s moved 4v1 and 2.10p on the ask.

Let’s see if next week breaks 2p and holds, in theory it should, as sellers aren’t around sub 2p.

Pretty sure we must be getting close to a biggish fund increase announcement, our recent high calibre Legal hire isn’t for thumb twiddling.

I suspect those adding into close had been waiting for a dip during the day which didn’t happen.

Good to see such solid support, bodes well for next week, and the months ahead which will be rich in newsflow.

Good post Gloria.

“A World First” to describe one of their products.

Interesting Volume here over the last week.

It suggests a number of investors taking proper positions.

Be careful not to trade out and into the void.

As we further develop our product portfolio, we have an opportunity to reach millions of people with novel pharmacogenetic tests. The Genedrive® CYP2C19 ID Kit detects specific alleles of the CYP2C19 gene to inform clinicians of an individual’s metaboliser status according to CPIC guidelines in treatment strategies using therapeutics that are metabolised by CYP2C19. This test is for use in point of care settings where routine prescribing would take place. This is also part of a NICE diagnostic assessment programme ‘Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack.’ Up to one in five patients are unable to convert clopidogrel into its active form, rendering it ineffective.

Ultimately, our goal is to change lives through rapid, near patient access to the benefits of molecular diagnostics in time critical settings. The value of pharmacogenetics in personalised medicine is indisputable. Removing the cost of ineffective prescriptions and reducing the burden of avoidable illness and adverse drug reactions could present a substantial cost-saving opportunity, in addition to optimising the efficacy and safety of the care received by each individual patient.

The WORLDS First.

These are important words for any investor.

Think slightly longer term than a few days.

NICE recommends genetic test to prevent newborn babies going deaf

The world's first point of care test to screen infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers of the variant are given aminoglycoside antibiotics. A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in draft guidance.

Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care – JAMA Pediatrics

The publication confirms Genedrive® MT-RNR1 test's role in avoiding antibiotic related hearing loss in infants. An important step in the management of neonatal sepsis. The PALOH study demonstrates the ease of use and capability of the Genedrive® technology to deliver rapid genetic information in a very time sensitive acute care situation.

Preventing stroke-related deaths and easing NHS burden with pharmacogenetic testing

Ahead of World Stroke Day, David Budd, CEO of genedrive plc, underscores the growing role of pharmacogenetics in personalised medicine and how its application can decrease the odds of secondary cerebrovascular disease.

Eerrr £31K.

Not chicken feed for anyone.

It’s funny, I’ve been investing in AIM for many years, occasionally picking and holding some incredible Companies, and making very significant profits.

True, I’ve lost plenty too along the way.

However, Formerly, breaking into the USA 🇺🇸 was the Holy Grail, inventing & developing a product/medicine into the largest economy in the World was such a major breakthrough for any micro-cap on the Alternative investment Market.

So, I await with patience to see how Genedrive progresses with the FDA and licensing in the great USA.

I’m curious too, with litigation so rife, compensation so huge, whether out tiny little Companies inventions may well prove to be of great interest.

Indeed, I’m very confident.

Remember, our CEO topped up 1Million in August at 3.1p.

Also, he’s built up & sold 2 previous pharma Companies for over £250M each, so he has form.

With a current MCap of £12M and circa £5M in cash we’re currently valued at £7M for what we have developed.

I’m holding for some real gains as I suspect there is significant potential here.

There’s a lot of significant news due here and having raised £6M recently any talk of placings and’ running out of cash’ is just troll/trader narrative.

Strong rebound due after brief retrace.

Exactly Porky.

Genedrive’s technology will save many many millions of pounds over current tests……

……..oh, and much more effective too, results in minutes rather than days.

That in itself should enable even the most nervous of investors to understand the benefits and therefore hold the stock for long enough to achieve realistic returns.

Conservative thoughts.

Remember, GDR is the market leader in this field, and that counts for a lot when valuations start being banded about.

It won’t take long for some figures to become extrapolated, and then the fun starts.

Plus we’re approved Stateside

Just raised £6 Million so cash not an issue.

3 products approved……..